ライフサイエンスコーパス: osteonectin

1 s between prostate cancer cells and bone via osteonectin.

2 at the mRNA level, including osteocalcin and osteonectin.

3 the invasive in vitro phenotype mediated by osteonectin.

4 antithrombin (TAT), factor V activation, and osteonectin.

5 Deregulated expression of SPARC/osteonectin, a secreted glycoprotein with multiple biolo

6 In this study, we show that SPARC/osteonectin, a small ECM-associated matricellular glycop

7 ourteen fragments from known genes including osteonectin (also known as SPARC and BM-40) were identif

8 e differentiation marker osteopontin, Fgfr1, osteonectin and alkaline phosphatase are down-regulated,

9 o structurally unrelated bone-related genes, osteonectin and osteoactivin, acquired a highly invasive

10 Two other genes (e.g., osteonectin and semaphorin 3B) are well characterized as

11 site overlaps those of SPARC (also known as osteonectin) and discodin domain receptor 2, but is more

12 ertain anti-adhesion molecules (versican and osteonectin), and poor in the pro-adhesive molecules ost

13 ulated genes were SNAI2, FGFBP1, VIM, SPARC (osteonectin), and SERPINE1, while the downregulated gene

14 The bone proteins, osteopontin, osteonectin, and bone sialoprotein, were identified in t

15 ences in clotting or product formation (FPA, osteonectin, and factor Va) were observed.

16 steogenic cell lineages including periostin, osteonectin, and Id2 are expressed specifically in the c

17 type I, clusterin, matrix glycoprotein sc1, osteonectin, and one unknown molecule (designated SIM).

18 last differentiation, including osteopontin, osteonectin, and osteocalcin.

19 ike alkaline phosphatase (ALP), osteopontin, osteonectin, and osteocalcin; and late markers like DMP2

20 ssions of alkaline phosphatase, osteocalcin, osteonectin, and osteopontin were analyzed along with in

21 extracellular matrix protein known as BM-40, osteonectin, and SPARC (secreted protein acidic and rich

22 ecreted protein, acidic and rich in cysteine/osteonectin, and thrombospondin 4.

23 rinogen, von Willebrand factor, factor V and osteonectin are decreased in concentration and significa

24 SPARC, also termed osteonectin, BM-40 and 43K protein, is an acidic, cystei

25 Secreted protein acidic and rich in cysteine/osteonectin/BM-40 (SPARC) is a matrix-associated protein

26 One of its component proteins, SPARC (osteonectin/BM-40), binds calcium and collagens, and can

27 , and the extracellular matrix protein SPARC/osteonectin/BM-40.

28 ells in part by stimulating the secretion of osteonectin by bone.

29 In vitro studies indicate that osteonectin can bind collagen and regulate angiogenesis,

30 ne morphogenetic proteins in an osteocalcein/osteonectin carrier (hBMP/NCP) (n=2 sites).

31 ctivated receptor gamma (PPARgamma), leptin, osteonectin, core binding factor 1 (CBFA1), and FBJ muri

32 Expression of osteonectin did not affect MDA-231 cell proliferation, a

33 ession models involve three key genes-SPARC (Osteonectin), Doublecortex, and Semaphorin3B-which play

34 e.g., alkaline phosphatase, type I collagen, osteonectin) during days 3-7, and the concomitant format

35 xpressing osteonectin to examine the role of osteonectin expression in breast cancer cells and its ef

36 Interestingly, high osteonectin expression in MDA-231 cells inhibited metast

37 d platelet aggregation in vitro and the high osteonectin expression in MDA-231 cells reduced tumor ce

38 d selected animal models for bone fragility, osteonectin expression is decreased.

39 Osteonectin expression was not blocked when melanoma cel

40 se (ALP), in vitro mineralization along with osteonectin expression, induction of apoptosis, and cyto

41 ly demonstrated that expression of the SPARC/osteonectin gene, while undetectable in the MCF7 cell li

42 tein components of bone matrix, collagen and osteonectin, have been shown to be substrates of the act

43 To determine the function of osteonectin in bone, we used contact x-ray, histomorphom

44 he expression of bone sialoprotein (BSP) and osteonectin in both femurs and bone marrow osteoblastic

45 s suggest that high endogenous expression of osteonectin in breast cancer cells may reduce metastasis

46 e up-regulated expression of VE-cadherin and osteonectin in breast tumor vasculature.

47 ecreted protein acidic and rich in cysteine)/osteonectin in insulin resistance but potential effects

48 n (statistically significant at P <0.01) and osteonectin in PDL cells relative to stimulation with do

49 We further show that recombinant osteonectin increased the invasiveness of PC-3 cells, wh

50 However, in vitro invasion of these osteonectin-infected cells through Matrigel and colony f

51 et-tumor cell aggregation, because exogenous osteonectin inhibited platelet aggregation in vitro and

52 d protein acidic and rich in cysteine)/BM 40/osteonectin is a matricellular protein shown to function

53 Osteonectin is abundant in bone and is expressed in area

54 Increased expression of osteonectin is found in malignant breast tumors.

55 BM-40 (also known as SPARC or osteonectin) is an anti-adhesive secreted glycoprotein i

56 ed protein, acidic and rich in cysteine), or osteonectin, is a matricellular protein.

57 ne (SPARC), originally discovered in bone as osteonectin, is a mediator of collagen deposition and pr

58 ased the invasiveness of PC-3 cells, whereas osteonectin-neutralizing antibodies blocked this p45-sEr

59 We found that osteonectin-null mice have decreased bone formation and

60 is to characterize the skeletal phenotype of osteonectin-null mice.

61 for osteoclasts; and the mineral regulators osteonectin (ON) and matrix Gla protein (MGP).

62 The region in human osteonectin (ON) responsible for binding to type V colla

63 Here we examined the effects of osteonectin (ON), a major factor secreted by SCs, on sur

64 alcin (OCN), alpha 2(1)(type 1) collagen and osteonectin (ON), were performed.

65 in, acidic and rich in cysteine, also called osteonectin or BM40), and collagen IV decreased, and fib

66 examination of tumor cells expressing either osteonectin or osteoactivin revealed that there was no i

67 e that the extracellular matrix glycoprotein osteonectin or secreted protein acidic and rich in cyste

68 lation of alkaline phosphatase, osteocalcin, osteonectin/osteopontin, and in vitro mineralized nodule

69 ghly abundant primary transcripts, including osteonectin, RACK1, calnexin, calreticulin, FTL, and B2M

70 Differences in platelet activation (osteonectin release) between normal and factor VIII-defi

71 prothrombin fragments, platelet activation (osteonectin release), factor Va generation, fibrinopepti

72 ells of the new bone were positive for human osteonectin showing their donor origin.

73 SPARC/Osteonectin (SP/ON) is implicated in the regulation of c

74 Osteonectin (SPARC, BM-40) is a bone matrix factor that

75 the secreted protein, acidic, cysteine-rich (osteonectin) (SPARC) gene, which encodes a matricellular

76 Deletion of osteonectin/SPARC causes age-onset cataract in mice and

77 Osteonectin/SPARC expression and/or secretion was monito

78 Western blot analysis revealed osteonectin/SPARC in both the macula and the peripheral

79 is study, the expression and localization of osteonectin/SPARC in the monkey retina were determined a

80 The expression pattern of osteonectin/SPARC in the subcellular retinal fractions i

81 Osteonectin/SPARC is a secreted protein that has been im

82 thern blot analysis shows that in the retina osteonectin/SPARC is expressed almost exclusively by the

83 cultured on porous substrates indicated that osteonectin/SPARC is secreted in large amounts from both

84 ollectively these data provide evidence that osteonectin/SPARC is synthesized in the macular RPE, sec

85 Outside of the retina osteonectin/SPARC mRNA is broadly expressed in many huma

86 Immunohistochemical analysis localized osteonectin/SPARC specifically to the outer plexiform la

87 n subcellular fractions of the whole retina, osteonectin/SPARC was detected, mainly in the soluble fr

88 ents, proteinases and inhibitors, galectins, osteonectin/SPARC, and prostaglandin D2 synthase.

89 at p45-sErbB3 up-regulated the expression of osteonectin/SPARC, biglycan, and type I collagen in calv

90 portion of SC1/ECM2 has sequence homology to osteonectin/SPARC, the unique N-terminal one fifth of th

91 ctous human lens has increased expression of osteonectin/SPARC.

92 Because osteonectin specifically enhances matrix metalloprotease

93 These data indicate that osteonectin supports bone remodeling and the maintenance

94 ell-conditioned medium is a low glycosylated osteonectin that specifically promotes the invasive abil

95 trix proteins (osteopontin, osteocalcin, and osteonectin) that regulate skeletal mineralization may o

96 t cancer cells with an adenovirus expressing osteonectin to examine the role of osteonectin expressio

97 bone is, in part, mediated by the ability of osteonectin to promote migration, protease activity, and

98 Expression of osteonectin was also associated with reduced adhesion to

99 Induction of osteonectin was confirmed by Northern and Western blot a

100 (panstromal expression), whereas the second (osteonectin) was specifically expressed within the juxta

101 steoblast promoters, such as osteopontin and osteonectin, was less sensitive to changes in gap juncti

102 >10 ng/mL, ALP, in vitro mineralization, and osteonectin were downregulated in PDL cells.

103 factor V activation, and release of platelet osteonectin were slower in factor XI-deficient blood tha

104 ncluding laminin, J6(Hsp 47), and J31(SPARC, osteonectin) were expressed at lower levels in RA-treate

105 essed lower levels of matrix Gla protein and osteonectin, whereas alkaline phosphatase, bone sialopro